Director Clinical Science

M&A roundup: Pathos AI enter's licensing agreements with AstraZeneca & Alphamab Oncology, Curium enters merger agreement with Lantheus. Pathos AI secured a $125 million upfront license to Alphamab's JSKN016 and a co-exclusive agreement with AstraZeneca to advance AZD4241, while Curium announced a deal to acquire Lantheus for up to $8 billion. Dealmaking across oncology and radiopharmaceuticals accelerated this week, with licensing agreements reshaping antibody-drug conjugate and breast cancer pipelines, alongside a multibillion-dollar merger in nuclear medicine. Patho AI licenses TROP2/HER3 bispecific ADC from Alphamab. Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals, a wholly-owned subsidiary of Alphamab Oncology, for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate independently developed by Alphamab.[1] Under the terms of the agreement, Alphamab is granting Pathos an exclusive license to research, develop, manufacture and commercialize JSKN016 outside the Chinese Mainland, Hong Kong, Macau and Taiwan, with Pathos expected to bear all related development and commercialization costs.[1] Alphamab retains full and exclusive rights to develop, manufacture and commercialize JSKN016 within those retained territories. As part of the deal, Alphamab is entitled to a non-refundable upfront payment of $125 million along with milestone payments tied to development and commercialization targets totaling up to $2,093 million, as well as tiered royalties at high-single digit to low-double digit percentage rates on aggregate annual net sales in the licensed territories.[1] JSKN016 is conjugated via site-specific glycosylation to generate a homogeneous and stable ADC with a drug-to-antibody ratio of 4. It binds to TROP2 and/or HER3 on tumor cells, blocks the corresponding signaling pathways and releases topoisomerase I inhibitors through cellular endocytosis to exert anti-tumor effects. "JSKN016 is a next-generation bispecific ADC with the potential to address significant unmet need across a range of solid tumors, and we are excited to advance it in partnership with Alphamab. This program was identified through Foundry, the same platform that continues to guide portfolio decisions across our clinical pipeline. This collaboration reflects our shared commitment to bringing differentiated therapies to patients," said Iker Huerga, chief executive officer of Pathos AI. Pathos AI and AstraZeneca advance AZD4241. Along with its licensing agreement with Alphamab, Pathos AI also announced a collaboration and co-exclusive licensing agreement with AstraZeneca, aiming to advance AZD4241, a preclinical investigational therapy for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.[2] As part of the deal, Pathos will assume responsibility for the asset's early clinical development. AZD4241 is an investigational oral PROTAC (proteolysis-targeting chimera) designed to degrade the estrogen receptor, targeting both normal and mutated forms of the receptor.[2] Mutated forms of the estrogen receptor are present in up to 30-40% of patients whose disease progresses on standard hormone therapies. "The bottleneck in oncology is not finding molecules. It is proving they work in the right patients. AZD4241 has a compelling mechanism. Foundry's job is to design the trial that proves it - matching this drug to the patients whose biology demands it. That is how we compress time. Patients are waiting," said Iker Huerga, chief executive officer of Pathos AI. The collaboration expands Pathos's clinical pipeline to three major assets across four distinct tumor types, AZD4241 for ER+/HER2- breast cancer, pocenbrodib for metastatic castration-resistant prostate cancerand relapsed/refractory multiple myeloma, and DO-2 for MET-altered non-small-cell lung cancer.[2] Curium to acquire lanthe. Curium announced that Curium U.S. Holdings LLC and Lantheus have entered into a definitive agreement under which Lantheus will merge with a wholly-owned subsidiary of Curium U.S.[3] As part of the agreement, Curium U.S. will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable contingent value rights providing for up to $12.00 per share in potential additional cash payments, subject to specified commercial milestones for Lantheus's products through 2030.[3] Total per-share consideration is up to $114.50, and the total transaction value is up to approximately $8.0 billion.[3] The transaction represents a premium of 38% to Lantheus's unaffected 60-day volume-weighted average price, 29% to its unaffected 30-day volume-weighted average price, and 21% to its unaffected closing price, each as of May 21, 2026, the last trading day before the first media report of a potential sale.[3] Lantheus's board of directors unanimously approved the transaction. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with infrastructure and capabilities to serve patients in more than 70 countries. "Lantheus is the ideal partner to accelerate what we have been building at Curium. We have executed a strategy to build an innovative, theranostics platform by expanding our global manufacturing footprint, advancing our radioligand therapy pipeline across key regions, and positioning Curium to drive the next generation of theranostics innovation," said Renaud Dehareng, chief executive officer of Curium Group.

Pathos inks back-to-back cancer contracts with AstraZeneca, China's Alphamab. August 4, 2026 | Pathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of the AstraZeneca agreement were not disclosed. Pathos AI has linked up with AstraZeneca and Suzhou-based Jiangsu Alphamab Biopharmaceuticals in a pair of partnerships that will beef up the New York drugmaker's clinical cancer pipeline. With Jiangsu Alphamab, a subsidiary of Alphamab Oncology, Pathos is paying $125 million upfront and has earmarked up to $2.093 billion in milestones for rights to a bispecific antibody-drug conjugate in late-stage development for breast cancer, according to a Monday release. The Chinese company also stands to receive tiered royalties in the high-single-digit to low-double-digit percentage range, based on annual net sales - granted the alliance asset reaches the market. Financial details of the AstraZeneca agreement, on the other hand, weren't revealed but the deal centers around the pharma's preclinical PROTAC degrader that is also targeting breast cancer, per a separate announcement on Monday. Across both Monday partnerships, Pathos will leverage its proprietary AI platform Foundry, which according to the company's website is built on the "largest oncology foundation model in the industry." By using "thousands" of AI agents, Foundry is able to analyze complex clinical, biological and real-world data to optimize trial design and dosing, as well as match patients to the safest treatments that are most likely to elicit therapeutic benefit, Pathos said on Monday. Under the AstraZeneca deal, Pathos will use Foundry to advance AZD4241, which targets and degrades the estrogen receptor. The asset is being proposed for ER+/HER2- breast cancer. Pathos will take charge of AZD4241's early-stage development informed directly by insights from Foundry. It is unclear at what point of the drug development process AstraZeneca will take over. From Jiangsu Alphamab, Pathos has in-licensed JSKN016 - itself a molecule "identified and prioritized through Foundry," the AI specialist said on Monday. JSKN016 is currently in pivotal development for later-line triple-negative breast cancer in China, where Jiangsu Alphamab will retain full rights over the asset, as well as in Hong Kong, Macau and Taiwan. With the deal, Pathos will have full control over JSKN016 in all other territories and be responsible for the asset's development and commercialization globally - again, as informed by insights from Foundry. "Every major asset-level decision at Pathos flows through Foundry," the company said on Monday. Jiangsu Alphamab is also studying JSKN016 in various types of breast cancer, non-small cell lung cancer and other advanced solid tumors. With the two new agreements, Pathos now has four assets in the clinic, alongside the early-stage pocenbrodib for prostate cancer, breast cancer and multiple myeloma, as well as Phase 2 P-500 for solid tumors.

Pathos AI enters collaboration and co-exclusive licensing agreement to advance novel erα PROTAC for ER+ breast cancer into the clinic. * 4 hrs ago Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a collaboration and co-exclusive licensing agreement with AstraZeneca. Under this agreement, the companies will advance AZD4241, a preclinical investigational therapy for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, with Pathos assuming responsibility for the early clinical development of the asset. AZD4241 is an investigational oral therapy known as a PROTAC (proteolysis-targeting chimera), specifically designed to degrade the estrogen receptor, targeting both normal and mutated forms of the receptor. Mutated forms of the estrogen receptor are present in up to 30-40% of patients whose disease progresses on standard hormone therapies. Powered By Keir Starmer arrives in Ankara for Nato summit Translating the full potential of this mechanism into patient benefit requires a fundamentally different approach. By harnessing large-scale multimodal patient data and a proprietary AI platform, Pathos redesigns drug development end-to-end. The company's capabilities span early asset identification, data driven portfolio optimization, and AI-native trial monitoring, with the specific early clinical execution for AZD4241 driven directly by its Foundry platform. Accelerated by AI: The Foundry Advantage In complex indications like ER+ breast cancer, identifying the exact patient subpopulation, optimal dose, and ideal treatment setting is a massive data challenge. Foundry was built to solve this problem. Foundry utilizes thousands of AI agents working in parallel, powered by the Pathos Oncology Foundation Model. These agents analyze complex biological, clinical, and real-world data to intelligently design clinical trials, optimize dosing, and match the right patients to the right therapies faster and more safely than traditional methods allow. "The bottleneck in oncology is not finding molecules. It is proving they work in the right patients. AZD4241 has a compelling mechanism. Foundry's job is to design the trial that proves it - matching this drug to the patients whose biology demands it. That is how we compress time. Patients are waiting." - Iker Huerga, CEO of Pathos AI A Growing Mission to Transform Oncology This collaboration and co-exclusive licence agreement to bring AZD4241 into the clinic expands Pathos' clinical pipeline to three major assets across four distinct tumor types. AZD4241, targeting ER+/HER2- breast cancer, joins pocenbrodib, currently in development for metastatic castration-resistant prostate cancer (mCRPC) and relapsed/refractory multiple myeloma (RRMM), and DO-2 for MET-altered non-small-cell lung cancer (NSCLC). Every program in the Pathos pipeline has been identified, evaluated, or accelerated by the Foundry platform, reinforcing the company's commitment to AI-native drug development. About Pathos AI Pathos AI is an AI and technology company advancing its own pipeline of cancer therapies. Its Foundry platform redesigns drug development from first principles: identifying undervalued clinical assets, making portfolio decisions with continuously updated probability-of-success calculations, and executing clinical trials with AI-native monitoring. Pathos's pipeline includes clinical-stage programs in mCRPC, multiple myeloma, and MET-altered NSCLC. Forward-Looking Statements This press release contains forward-looking statements. These statements involve risks and uncertainties that may cause actual results to differ materially. Pathos AI undertakes no obligation to update any forward-looking statement. Media gallery Sections.